Clinical Trial Update: Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies [Phase 1]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 1 safety study investigating cetuximab plus dasatinib in patients with advanced solid malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ERBITUX (cetuximab)
• Sprycel (dasatinib)

Snippet

Sponsor: University of Pittsburgh | Conditions: Malignant Solid Tumour | Phase 1 | Status: COMPLETED